Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing comprehensive research and development services to clients across multiple industries. The company's core business model revolves around its Cell Engineering segment, which functions as an outsourced R&D partner for companies seeking to develop biological products. Ginkgo leverages its automated laboratory facilities, alongside data analytics and artificial intelligence, to design, build, and test custom organisms. These engineered cells are utilized in a wide array of applications, ranging from the discovery of novel therapeutics and genetic medicines to the production of agricultural biologicals, industrial chemicals, and food ingredients.
Historically, Ginkgo also operated a Biosecurity segment, which provided biomonitoring and public health surveillance services to government and enterprise customers. However, in April 2026, the company completed the strategic divestiture of its Biosecurity business, shifting its focus entirely to its core cell engineering tools and services. As a result, 100% of the company's continuing operations revenue is now derived from its Cell Engineering segment. Ginkgo generates revenue through a combination of upfront research and development fees, milestone payments upon the successful completion of engineering targets, and downstream value-sharing agreements such as royalties or equity stakes in client projects. Geographically, the company is headquartered in Boston, Massachusetts, and serves a global clientele spanning the pharmaceutical, biotechnology, agricultural, and consumer goods sectors.
